Outcome Sample Size Result Without Treatment Result With Treatment (Observed) Result With Treatment (Calculated) Effect Estimate Certainty of Evidence What this means Systolic blood pressure at 12 weeks 62 participants, 60 analyzed, 53 without missing data [No summary statement.] [No summary statement.] [No summary statement.] difference in means -4.5 mm Hg (95% confidence interval -10.82 mm Hg to 1.32 mm Hg) [No summary statement.] [No summary statement.] Diastolic blood pressure at 12 weeks 62 participants, 60 analyzed, 53 without missing data [No summary statement.] [No summary statement.] [Not a proportion.] difference in means -4.92 mm Hg (95% confidence interval -8.58 mm Hg to 0.27 mm Hg) [No summary statement.] [No summary statement.] Medication Adherence at 12 weeks 62 participants, 53 without missing data 70% 65.6% 46.33% odds ratio 0.37 (95% confidence interval 0.19 to 2.08) [No summary statement.] [No summary statement.] Hypertension Control at 12 weeks 62 participants, 60 analyzed, 53 without missing data 54.17% 65.52% 77.11% odds ratio 2.85 (95% confidence interval 0.94 to 8.59) [No summary statement.] [No summary statement.] Add-on Amlodipine at 6 weeks 62 participants, 60 analyzed, 62 without missing data, 22 events 53.33% 18.75% 51.25% odds ratio 0.92 (95% confidence interval 0.02 to 0.41) [No summary statement.] [No summary statement.] Adverse event free and hypertension control at 12 weeks 62 participants, 53 analyzed, 53 without missing data, 13 events 33.33% 17.24% 29.33% odds ratio 0.83 (95% confidence interval 0.22 to 3.16) [No summary statement.] [No summary statement.]
Outcome Measure Report for QUARTET USA Trial
Summary of Findings - QUARTET USA Trial [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 397488. Revised 2025-09-03. Available at: https://fevir.net/resources/Composition/397488. Computable resource at: https://fevir.net/resources/Composition/397488.
No need for narrative text.
Outcome
Sample Size
Result Without Treatment
Result With Treatment (Observed)
Result with intervention alone (calculated)
result with intervention with calculated value derived from the control group and effect estimate
Result With Treatment (Calculated)
Effect Estimate
Certainty of Evidence
What this means
[No data.]
Results for Systolic blood pressure at 12 weeks
Summary of findings entry for a single outcome
Systolic blood pressure at 12 weeks
62 participants, 60 analyzed, 53 without missing data
Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
[Not a proportion.]
Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
difference in means -4.5 mm Hg (95% confidence interval -10.82 mm Hg to 1.32 mm Hg)
[No certainty rating found.]
[No assertion provided.]
Results for Diastolic blood pressure at 12 weeks
Diastolic blood pressure at 12 weeks
Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
difference in means -4.92 mm Hg (95% confidence interval -8.58 mm Hg to 0.27 mm Hg)
Results for Medication Adherence at 12 weeks
Medication Adherence at 12 weeks
62 participants, 53 without missing data
Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
70%
Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
odds ratio 0.37 (95% confidence interval 0.19 to 2.08)
Results for Hypertension Control at 12 weeks
Hypertension Control at 12 weeks
Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
odds ratio 2.85 (95% confidence interval 0.94 to 8.59)
Results for Add-on Amlodipine at 6 weeks
Add-on Amlodipine at 6 weeks
62 participants, 60 analyzed, 62 without missing data, 22 events
Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
odds ratio 0.92 (95% confidence interval 0.02 to 0.41)
Results for Adverse event free and hypertension control at 12 weeks
Adverse event free and hypertension control at 12 weeks
62 participants, 53 analyzed, 53 without missing data, 13 events
Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
odds ratio 0.83 (95% confidence interval 0.22 to 3.16)